Cart
sales@molnova.com
ANA975
CAS No. 847453-47-8
ANA975( ANA 975 )
Catalog No. M16149 CAS No. 847453-47-8
ANA975 is an oral prodrug of the TLR-7 agonist Isatoribine (ANA245;7-Thia-8-oxoguanosine) against hepatitis C virus (HCV) infection.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 873 | Get Quote |
|
| 50MG | 1782 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameANA975
-
NoteResearch use only, not for human use.
-
Brief DescriptionANA975 is an oral prodrug of the TLR-7 agonist Isatoribine (ANA245;7-Thia-8-oxoguanosine) against hepatitis C virus (HCV) infection.
-
DescriptionANA975 is an oral prodrug of the TLR-7 agonist Isatoribine (ANA245;7-Thia-8-oxoguanosine) against hepatitis C virus (HCV) infection.HCV Infection Phase 1 Discontinued.
-
In Vitro——
-
In Vivo——
-
SynonymsANA 975
-
PathwayImmunology/Inflammation
-
TargetTLR
-
RecptorTLR
-
Research AreaInfection
-
IndicationHCV Infection
Chemical Information
-
CAS Number847453-47-8
-
Formula Weight384.363
-
Molecular FormulaC14H16N4O7S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC[C@@H]1[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](N(C2=NC(N)=NC=C2S3)C3=O)O1
-
Chemical Name(2R,3R,4R,5R)-2-(5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diyl diacetate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Xiang AX, et al. Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40.
molnova catalog
related products
-
GSK2245035
GSK2245035 is a highly potent, selective TLR7 agonist that selectively induces TFN-α in PBMC assays with pEC50 of 9.3, >2 logs selectivity over TNFα pEC50.
-
MMG-11
MMG-11 is a potent and selective human TLR2 antagonist with low cytotoxicity. MMG-11 inhibits both TLR2/1 and TLR2/6 signaling with IC50s of 1.7?μM for Pam3CSK4-induced hTLR2/1 and 5.7?μM for Pam2CSK4-induced hTLR2/6 responses.
-
TLR7/8-IN-1
TLR7/8-IN-1, a crystalline TLR7/TLR8 inhibitor from patent WO2019220390 (compound 2b), is a valuable compound for autoimmune disease research.
